Suzhou Ribo Life Science Co
Status: Publicly traded
Direct answer
Suzhou Ribo Life Science Co is publicly traded on HKSE under the ticker 6938.HK.
Suzhou Ribo Life Science Co., Ltd. researches and develops novel therapeutics for the treatment of cardiovascular, metabolic, renal, and liver diseases in Chinese mainland and internationally. It develops RBD4059, which is phase 2 clinical trial for treating thrombotic diseases; RBD5044 that is in phase 2 clinical trial for treating hypertrigly ceridemia; RBD7022, which is in phase 2 clinical trial for the treatment...
Can you invest in Suzhou Ribo Life Science Co?
Yes. Suzhou Ribo Life Science Co is publicly traded on HKSE under the ticker 6938.HK.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Suzhou Ribo Life Science Co
Detailed equity research is provided by MarketSnap.